1. Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. New England Journal of Medicine, 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1908142?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute, 2019. https://goldcopd.org.uploads.2019
3. Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI. Laporan Hasil Riset Kesehatan Dasar (RISKESDAS) 2013. LITBANG DEPKES RI. Jakarta. 2013.
4. Puente-Maestu L, Álvarez-Sala LA and Miguel-Díez J. Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses. COPD Research and Practice, 2015, 1:11.
5. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Mark TD. Beta-blockers in COPD: time for reappraisal. Eur Respir, 2016; 48: 880–888.
6. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE, 2014. 9(11): e113048. doi:10.1371/journal.pone.0113048.
7. Maltais F, Buhi R, Koch A, Amatto VC, Reid J et al. Beta-Blocker in COPD. A Cohort Study from The TONADO Research Program. CHEST 2019; 153(6):1315-1325.
8. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71: 8–14.
9. Gulea, C., Zakeri, R., Alderman, V. et al. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res 22, 64 (2021). https://doi.org/10.1186/s12931-021-01661-8
Facebook 
Masuk dengan Email
